These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 10764152)

  • 1. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7.
    Issaad C; Ahmed M; Novault S; Bonnet ML; Bennardo T; Varet B; Vainchenker W; Turhan AG
    Leukemia; 2000 Apr; 14(4):662-70. PubMed ID: 10764152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
    Zhang X; Ren R
    Blood; 1998 Nov; 92(10):3829-40. PubMed ID: 9808576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of the erythropoietin-induced erythroid differentiation by granulocyte-macrophage colony-stimulating factor in the human UT-7 cell line is not due to a negative regulation of the erythropoietin receptor.
    Hermine O; Dubart A; Porteux F; Mayeux P; Titeux M; Dumenil D; Vainchenker W
    Blood; 1996 Mar; 87(5):1746-53. PubMed ID: 8634420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primitive interleukin 3 null hematopoietic cells transduced with BCR-ABL show accelerated loss after culture of factor-independence in vitro and leukemogenic activity in vivo.
    Jiang X; Ng E; Yip C; Eisterer W; Chalandon Y; Stuible M; Eaves A; Eaves CJ
    Blood; 2002 Nov; 100(10):3731-40. PubMed ID: 12393460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR-ABL does not prevent apoptotic death induced by human natural killer or lymphokine-activated killer cells.
    Roger R; Issaad C; Pallardy M; Léglise MC; Turhan AG; Bertoglio J; Bréard J
    Blood; 1996 Feb; 87(3):1113-22. PubMed ID: 8562937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid generation of a tetracycline-inducible BCR-ABL defective retrovirus using a single autoregulatory retroviral cassette.
    Dugray A; Geay JF; Foudi A; Bonnet ML; Vainchenker W; Wendling F; Louache F; Turhan AG
    Leukemia; 2001 Oct; 15(10):1658-62. PubMed ID: 11587226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemic target susceptibility to natural killer cytotoxicity: relationship with BCR-ABL expression.
    Baron F; Turhan AG; Giron-Michel J; Azzarone B; Bentires-Alj M; Bours V; Bourhis JH; Chouaib S; Caignard A
    Blood; 2002 Mar; 99(6):2107-13. PubMed ID: 11877286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of interleukin-3/granulocyte-macrophage colony-stimulating factor receptor beta-chain in BCR-ABL(+) human leukemic cells: association with loss of cytokine-mediated Stat-5 activation and protection from apoptosis after BCR-ABL inhibition.
    Donato NJ; Wu JY; Zhang L; Kantarjian H; Talpaz M
    Blood; 2001 May; 97(9):2846-53. PubMed ID: 11313280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid leukemia-like myeloproliferative disease in mice by BCR/ABL.
    Li S; Gillessen S; Tomasson MH; Dranoff G; Gilliland DG; Van Etten RA
    Blood; 2001 Mar; 97(5):1442-50. PubMed ID: 11222392
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression.
    Klucher KM; Lopez DV; Daley GQ
    Blood; 1998 May; 91(10):3927-34. PubMed ID: 9573031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p210 Bcr-Abl expression in a primitive multipotent haematopoietic cell line models the development of chronic myeloid leukaemia.
    Pierce A; Owen-Lynch PJ; Spooncer E; Dexter TM; Whetton AD
    Oncogene; 1998 Aug; 17(5):667-72. PubMed ID: 9704934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered IFNgamma signaling and preserved susceptibility to activated natural killer cell-mediated lysis of BCR/ABL targets.
    Cebo C; Voutsadakis IA; Da Rocha S; Bourhis JH; Jalil A; Azzarone B; Turhan AG; Chelbi-Alix M; Chouaib S; Caignard A
    Cancer Res; 2005 Apr; 65(7):2914-20. PubMed ID: 15805294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL fails to inhibit apoptosis in U937 myelomonocytic cells expressing a carboxyl-terminal truncated STAT5.
    Ahmed M; Dusanter-Fourt I; Dugray A; Dubrez L; Novault S; Bonnet ML; Gisselbrecht S; Varet B; Solary E; Vainchenker W; Turhan AG
    Leuk Lymphoma; 2001 Jul; 42(3):445-55. PubMed ID: 11699409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
    Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
    Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of IFN-alpha and IFN-alpha combined with GM-CSF on expression of the genes related to cell apoptosis of MNCs from bone marrow in CML patients].
    Tang LJ; Chen HC; Peng XH
    Hunan Yi Ke Da Xue Xue Bao; 2000 Dec; 25(6):570-2. PubMed ID: 12516408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis.
    Perrotti D; Bonatti S; Trotta R; Martinez R; Skorski T; Salomoni P; Grassilli E; Lozzo RV; Cooper DR; Calabretta B
    EMBO J; 1998 Aug; 17(15):4442-55. PubMed ID: 9687511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of granulocyte-macrophage colony-stimulating factor in Philadelphia (Ph1)-positive acute lymphoblastic leukemia: studies on two newly established Ph1-positive acute lymphoblastic leukemia cell lines (Z-119 and Z-181).
    Estrov Z; Talpaz M; Zipf TF; Kantarjian HM; Ku S; Ouspenskaia MV; Hirsch-Ginsberg C; Huh Y; Yee G; Kurzrock R
    J Cell Physiol; 1996 Mar; 166(3):618-30. PubMed ID: 8600166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate apoptosis response gene-4 (par-4) abrogates the survival function of p185(BCR-ABL) in hematopoietic cells.
    Kukoc-Zivojnov N; Puccetti E; Chow KU; Bergmann M; Ruthardt M; Hoelzer D; Mitrou PS; Weidmann E; Boehrer S
    Exp Hematol; 2004 Jul; 32(7):649-56. PubMed ID: 15246161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BCR-ABL activates pathways mediating cytokine independence and protection against apoptosis in murine hematopoietic cells in a dose-dependent manner.
    Cambier N; Chopra R; Strasser A; Metcalf D; Elefanty AG
    Oncogene; 1998 Jan; 16(3):335-48. PubMed ID: 9467959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.